APA (7th ed.) Citation

Hong Tao, Zhe Liu, Jing Mu, Fei Gai, Zhan Huang, & Liang Shi. (2022). Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively. BMC.

Chicago Style (17th ed.) Citation

Hong Tao, Zhe Liu, Jing Mu, Fei Gai, Zhan Huang, and Liang Shi. Concomitant Novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion Variants and Confer Sensitivity to Crizotinib in Two Lung Adenocarcinoma Patients, Respectively. BMC, 2022.

MLA (9th ed.) Citation

Hong Tao, et al. Concomitant Novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion Variants and Confer Sensitivity to Crizotinib in Two Lung Adenocarcinoma Patients, Respectively. BMC, 2022.